Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model

Fig. 4

Comparison treatment efficacies and Analysis of interactions among treatments. The overall efficacy of 5-FU treatment, anti-CD25 treatment, and combination therapy was plotted as the percentage of tumor growth inhibition using instantaneous tumor size (first panel) and average tumor size (second panel) as outcomes. The blue line represents the inhibition percentage of tumor growth under 5-FU treatment on days 1, 2, 3, and 4 after tumor injection calculated based on the instantaneous tumor size during time and the red line under anti-CD25 treatment on days 3, 6, 10, 13, 17 and 20 after tumor inoculation and yellow line under combination therapy. (Third panel) The Bliss combination index (CI) for 5-FU and Anti-CD25treatments combination using instantaneous tumor size (CI inst) and average tumor size (CI ave) as an outcome. CI < 1 represents the synergistic effect of two treatments, CI = 1 additive, and CI > 1 antagonistic effect. The green dash-line indicates the threshold below which the 5-FU treatment and anti-CD25 treatment have a synergistic effect

Back to article page